Protocol for determining zinc-dependent β cell-selective small-molecule delivery in mouse pancreas

Area of Science:

• Biomedical Engineering
• Pharmacology
• Endocrinology

Background:

• Targeted drug delivery to pancreatic islet beta cells remains a significant clinical challenge.
• Beta cells exhibit a distinctively high intracellular zinc (Zn2+) concentration.
• Exploiting this Zn2+ characteristic offers a novel strategy for selective drug accumulation.

Purpose of the Study:

• To present a protocol for evaluating molecules designed for targeted delivery to pancreatic islet beta cells.
• To assess a molecule's ability to chelate islet Zn2+, accumulate within islets, and promote beta cell replication.
• To establish a reliable LC-MS/MS method for quantifying compound levels in biological samples.

Main Methods:

• Utilizing Zn2+-binding activity in small molecules to direct drug accumulation towards beta cells.
• Employing a protocol to evaluate Zn2+ chelation, islet accumulation, and beta cell-selective replication in mouse models.
• Developing and validating an LC-MS/MS assay for precise compound measurement.

Main Results:

• Demonstrated a method to assess Zn2+-binding molecules for beta cell targeting.
• Showcased the potential for stimulating beta cell replication through targeted delivery.
• Identified challenges in compound measurement, including ionizability and assay timing.

Conclusions:

• Integrating Zn2+-binding capacity into small molecules is a promising approach for targeted pancreatic beta cell drug delivery.
• The presented protocol facilitates the evaluation of such targeted therapeutic strategies.
• Further optimization of analytical methods is crucial for the successful implementation of this approach.